1,956 Shares in Abbott Laboratories (NYSE:ABT) Acquired by B.O.S.S. Retirement Advisors LLC

B.O.S.S. Retirement Advisors LLC bought a new stake in Abbott Laboratories (NYSE:ABT) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,956 shares of the healthcare product maker’s stock, valued at approximately $221,000.

Several other hedge funds also recently modified their holdings of the business. Toth Financial Advisory Corp lifted its stake in shares of Abbott Laboratories by 8.1% in the 4th quarter. Toth Financial Advisory Corp now owns 103,700 shares of the healthcare product maker’s stock valued at $11,730,000 after purchasing an additional 7,814 shares during the last quarter. CFS Investment Advisory Services LLC lifted its position in shares of Abbott Laboratories by 3.1% in the fourth quarter. CFS Investment Advisory Services LLC now owns 18,469 shares of the healthcare product maker’s stock worth $2,089,000 after buying an additional 558 shares during the last quarter. Grimes & Company Inc. increased its holdings in shares of Abbott Laboratories by 0.3% during the 4th quarter. Grimes & Company Inc. now owns 58,124 shares of the healthcare product maker’s stock valued at $6,574,000 after acquiring an additional 179 shares during the last quarter. Linden Thomas Advisory Services LLC lifted its holdings in Abbott Laboratories by 8.6% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 31,308 shares of the healthcare product maker’s stock worth $3,541,000 after purchasing an additional 2,488 shares during the last quarter. Finally, Cyndeo Wealth Partners LLC boosted its position in Abbott Laboratories by 1.2% during the fourth quarter. Cyndeo Wealth Partners LLC now owns 178,939 shares of the healthcare product maker’s stock worth $20,240,000 after purchasing an additional 2,179 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 1.5 %

Shares of ABT stock opened at $125.12 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The firm has a fifty day moving average of $115.26 and a 200-day moving average of $113.31. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $125.67. The stock has a market cap of $217.01 billion, a price-to-earnings ratio of 16.36, a P/E/G ratio of 2.51 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, hitting analysts’ consensus estimates of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The firm had revenue of $10.97 billion during the quarter, compared to analysts’ expectations of $11,029,400 billion. During the same quarter last year, the company earned $1.19 earnings per share. The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. On average, equities research analysts forecast that Abbott Laboratories will post 5.15 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be paid a dividend of $0.59 per share. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 annualized dividend and a yield of 1.89%. The ex-dividend date is Wednesday, January 15th. Abbott Laboratories’s dividend payout ratio is currently 30.85%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ABT shares. Piper Sandler boosted their price objective on shares of Abbott Laboratories from $131.00 to $133.00 and gave the stock an “overweight” rating in a research note on Thursday, October 17th. Wells Fargo & Company upped their price target on shares of Abbott Laboratories from $133.00 to $136.00 and gave the company an “overweight” rating in a report on Thursday. Barclays lifted their price objective on Abbott Laboratories from $143.00 to $149.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Sanford C. Bernstein raised their target price on Abbott Laboratories from $133.00 to $138.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Finally, Stifel Nicolaus upped their price target on Abbott Laboratories from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $132.50.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.